First Trust Advisors LP Cuts Stake in Thermo Fisher Scientific Inc. $TMO

First Trust Advisors LP decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 37.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 43,524 shares of the medical research company’s stock after selling 26,578 shares during the period. First Trust Advisors LP’s holdings in Thermo Fisher Scientific were worth $21,393,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Magellan Asset Management Ltd raised its stake in shares of Thermo Fisher Scientific by 10.1% during the 1st quarter. Magellan Asset Management Ltd now owns 83,187 shares of the medical research company’s stock worth $40,889,000 after buying an additional 7,605 shares in the last quarter. Investidor Profissional Gestao de Recursos Ltda. purchased a new stake in shares of Thermo Fisher Scientific in the first quarter valued at approximately $1,948,000. Oslo Pensjonsforsikring AS acquired a new position in Thermo Fisher Scientific during the first quarter worth $886,000. HORAN Wealth LLC raised its position in Thermo Fisher Scientific by 107.8% in the first quarter. HORAN Wealth LLC now owns 14,028 shares of the medical research company’s stock worth $6,989,000 after acquiring an additional 7,278 shares in the last quarter. Finally, Andra AP fonden lifted its holdings in Thermo Fisher Scientific by 1,411.9% in the first quarter. Andra AP fonden now owns 57,814 shares of the medical research company’s stock valued at $28,417,000 after acquiring an additional 53,990 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $577.38 on Thursday. The firm has a market capitalization of $214.56 billion, a PE ratio of 31.06, a P/E/G ratio of 2.35 and a beta of 0.87. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $643.99. The firm’s 50-day simple moving average is $501.43 and its 200 day simple moving average is $511.85. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period last year, the firm posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.

Insider Activity

In related news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $565.00, for a total value of $226,000.00. Following the sale, the chief operating officer owned 24,651 shares of the company’s stock, valued at approximately $13,927,815. This represents a 1.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

TMO has been the topic of a number of recent analyst reports. Wall Street Zen cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Robert W. Baird decreased their price objective on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Sanford C. Bernstein assumed coverage on shares of Thermo Fisher Scientific in a research report on Friday, June 26th. They set a “market perform” rating and a $520.00 target price on the stock. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Finally, Barclays boosted their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a research note on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $617.14.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.